HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Meth Fight Pits Rx-Only Pseudoephedrine Against E-Tracking Option

This article was originally published in The Tan Sheet

Executive Summary

The debate over how best to keep methamphetamine precursors from diversion to illicit drug labs is coming to a head as lawmakers stake out positions and legislation to restrict nonprescription access to pseudoephedrine waits in the wings

You may also be interested in...



Missouri Looks Beyond Electronic Tracking To Rx-Only PSE In Meth Fight

Missouri's governor supports a prescription-only pseudoephedrine law, marking the latest state-level movement toward restricting access to the decongestant and precursor of methamphetamine.

CVS' Combat Meth Compliance Failings Could Fuel PSE Rx-Only Movement

A lapse in CVS' tracking of methamphetamine precursor purchases cost the drugstore chain $75 million in civil penalties and could bolster arguments that pseudoephedrine should be available by prescription only

House Panel Gives Life To Enhancing Combat Meth Act

Legislation to bolster existing methamphetamine prevention regulations got a push from a House Energy and Commerce subcommittee July 22 after lying dormant for a year

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel